Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

SAN ANTONIO, and SAN FRANCISCO, Dec. 12, 2010 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in patients with metastatic breast cancer during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).  NKTR-102, a novel investigational topoisomerase I inhibitor-polymer conjugate, is Nektar's lead oncology candidate and is being evaluated in multiple cancer indications.  The randomized Simon two-stage study presented at SABCS evaluated two 145 mg/m2 dose schedules of single-agent NKTR-102, every two weeks (q14d) and every three weeks (q21d), in 70 metastatic breast cancer patients who failed a prior taxane therapy.  Eighty-seven percent (61/70) of patients in the study received a prior anthracycline/taxane with or without capecitabine.

More than one million women worldwide are diagnosed with breast cancer every year and anywhere from 30% to 80% develop metastatic disease.(1)  

A total of 66 of the 70 patients treated in the Phase 2 study were assessable for the primary endpoint of objective tumor response rate (ORR),  including confirmed complete and partial responses per RECIST.  As of October 26, 2010, confirmed ORR for all evaluable patients was 32% (10/31) for the q14d schedule and 26% (9/35) for the q21d schedule, including two confirmed complete responses (CRs) on the q14d schedule.  An additional four patients had near CRs, with 100% disappearance of all target lesions.  The combined ORR for all evaluable patients was 29% (19/66).  Clinical benefit rate for the 66 evaluable patients was 41% (defined as CR+PR+SD greater than or equal to 6 mos).

"These are important new results for NKTR-102 in patients with metastatic breast cancer," said Prof. Ahmad Awada, Head of the Medical Oncology Clinic
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)...  Cepheid (Nasdaq: CPHD ) today reported ... million, representing growth of 15% from $100.1 million for ... third quarter of 2014 was $(7.2) million, or $(0.10) ... million, or $(0.02) per share, in the third quarter ... amortization of debt discount and transaction costs, and amortization ...
(Date:10/16/2014)... 2014   DaVita HealthCare Partners Inc. ... nation,s largest and most innovative health care communities, ... HealthCare Partners 37 th overall in its ... Harvard Business Review (HBR). ... companies based on reputation strength, considers seven key ...
(Date:10/16/2014)... , Oct. 16, 2014 Eight finalists, all ... selected to present their proposals for a chance to ... the Sheikh Zayed Institute Second Annual Pediatric Surgical ... System on Friday, Oct. 24, 2014. ... from across the US and internationally, the finalists are: ...
Breaking Medicine Technology:Cepheid Reports 2014 Third Quarter Results 2Cepheid Reports 2014 Third Quarter Results 3Cepheid Reports 2014 Third Quarter Results 4Cepheid Reports 2014 Third Quarter Results 5Cepheid Reports 2014 Third Quarter Results 6Cepheid Reports 2014 Third Quarter Results 7Cepheid Reports 2014 Third Quarter Results 8Cepheid Reports 2014 Third Quarter Results 9Cepheid Reports 2014 Third Quarter Results 10Cepheid Reports 2014 Third Quarter Results 11Cepheid Reports 2014 Third Quarter Results 12Cepheid Reports 2014 Third Quarter Results 13Cepheid Reports 2014 Third Quarter Results 14Cepheid Reports 2014 Third Quarter Results 15Cepheid Reports 2014 Third Quarter Results 16Cepheid Reports 2014 Third Quarter Results 17Harvard Business Review Recognizes DaVita HealthCare Partners 2Harvard Business Review Recognizes DaVita HealthCare Partners 3Finalists for Children's National Health System pediatric medical device competition announced 2Finalists for Children's National Health System pediatric medical device competition announced 3Finalists for Children's National Health System pediatric medical device competition announced 4
... swiftly authorize a Special Enrollment Period to allow patients to ... if the patient believes that material misrepresentations led them to ... access, the National Community Pharmacists Association (NCPA) said ... year on January 1, local pharmacists have heard repeated complaints ...
... Jan. 19, 2012 /PRNewswire-Asia/ -- China Health Resource, Inc. ... based product line has experienced double digit sales growth ... line is expected to generate an estimated 50 million ...  The strength of the Company,s core product lines and ...
Cached Medicine Technology:Pharmacists Ask Medicare to Help Seniors Complaining About Inadequate Pharmacy Access in Medicare Prescription Drug Plans 2Pharmacists Ask Medicare to Help Seniors Complaining About Inadequate Pharmacy Access in Medicare Prescription Drug Plans 3China Health Resource Pharmaceutical Grade Gastrodia Product Line Expected to Contribute $8 Million in Revenue to 2011 Year End 2China Health Resource Pharmaceutical Grade Gastrodia Product Line Expected to Contribute $8 Million in Revenue to 2011 Year End 3
(Date:10/19/2014)... 19, 2014 Visual Impact Frequency ... just been released to the public generating a ... building and fitness community. The commotion surrounding the ... Vin Delmonico prompting an investigative review. , "Many ... what is commonly known as a training 'plateau' ...
(Date:10/19/2014)... stem cell-based research could improve understanding of intestinal diseases ... suggests. Scientists used stem cells to grow "organoids" ... They then transplanted the organoids into mice, creating a ... researchers. "This provides a new way to study ... failure, from genetic disorders appearing at birth to conditions ...
(Date:10/19/2014)... OCTOBER 20, 2014 – The U.S. Government has ... treat Alzheimer,s disease by 2025. However, a workgroup ... the research milestones in the U.S. Government,s National ... in scope, increased in scale, and adequately funded ... series of proposals by the workgroup to enlarge ...
(Date:10/19/2014)... NY (PRWEB) October 19, 2014 Nearly ... Bard Inc. and Johnson & Johnson’s Ethicon unit have ... Court, where two state proceedings are continuing to move ... 7,201 lawsuits have been filed over products part of ... Case List updated on October 11th, 2014, which showed ...
(Date:10/19/2014)... Denver, Colorado (PRWEB) October 19, 2014 ... consider joining Colorado and Washington State in the outright ... some words of advice for pro-cannabis activists in those ... framework is in place, or prepare for chaos. , ... The Denver-based shop is one of Colorado’s first recreational ...
Breaking Medicine News(10 mins):Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 4Health News:Cannabis CEO Warns Those States Considering a Legal Marijuana Market to Do Their Homework First 2Health News:Cannabis CEO Warns Those States Considering a Legal Marijuana Market to Do Their Homework First 3
... WASHINGTON, May 9, 2011 Flakes of skin that people ... are not just a nuisance the source of dandruff, ... actually can be beneficial. A new study, published in the ... concludes that oil in those skin cells makes a small ...
... 2011) The John Theurer Cancer Center at Hackensack ... Symposium on Friday, May 20 from 7:30am - 1:00pm. ... latest neuro-oncology trends by leaders in the field. ... to bring together leaders in neuro-oncology to provide insights ...
... out in Valencia shows that 37.4% of children aged from 6 to ... those aged from 12 to 15 wake up feeling refreshed only once ... 4.26% of them fall asleep in class more than three times per ... sleep throughout our lives depends on how we learn to sleep as ...
... invaluable procedure for detecting problems in the colon and ... catch the warning signs of colorectal cancer. Perfecting the ... just how much practice makes perfect? That was ... Clinic research team set out to answer in their ...
... , SUNDAY, May 8 (HealthDay News) -- People ... the disorder, even if they show no symptoms, a new ... digestive problems in the small intestine when the person consumes ... number of U.S. residents with the disease has grown rapidly ...
... HealthDay Reporter , MONDAY, May 9 (HealthDay News) ... often get unneeded CT scans that expose them to high ... the outcomes of more than 40,000 children treated for minor ... 2004 and September 2006. They found that four to six ...
Cached Medicine News:Health News:The skinny on how shed skin reduces indoor air pollution 2Health News:The John Theurer Cancer Center to host Seventh Annual Neuro-Oncology Symposium 2Health News:One-third of Spanish children do not wake up feeling refreshed 2Health News:Mayo Clinic studies how much practice makes perfect when performing colonoscopies 2Health News:More People May Benefit From Going Gluten-Free 2Health News:Child's Head Injury Doesn't Always Need CT Scan: Study 2Health News:Child's Head Injury Doesn't Always Need CT Scan: Study 3
... planning capabilities such as automatic image fusion ... arc settings or for frameless procedures. ... Improving the OR workflow . Flexible ... surgeon the flexibility to start the planning ...
Eye Bank Specular Microscope. Specular microscope for easy examination of corneal slice extracted from a donor....
... uses prolene as thread-guide reducing time and trauma ... is inserted into the nasolacrimal duct and a ... probe is then withdrawn leaving the polypropylene thread ... silicone tubing into place. Newly coated with a ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
Medicine Products: